Pharmaceutical firm Zydus Cadila and Germany-based Pieris AG on Wednesday announced an alliance for development and commercialisation of multiple novel Anticalin-based protein therapeutics.
The collaboration combines Pieris’ drug discovery and early development capabilities with Zydus’ expertise in biologics development, regulatory affairs and biologics manufacturing.
Under the terms of the agreement, Zydus will take the lead in advancing Anticalin drug candidates through formal pre-clinical development and into clinical development, undertaking drug development in accordance with the ICH guidelines.
Zydus has been granted exclusive marketing rights in India and several other emerging markets, while Pieris retains exclusive marketing rights in key developed markets, according to a press statement.
Pieris CEO, Stephen Yoder, said: “this collaboration will allow Pieris to unlock value on a global scale in a cost-effective manner, significantly expanding the number of proprietary Anticalin programmes we can advance into clinical trials.